{"id":61973,"date":"2025-10-04T04:02:36","date_gmt":"2025-10-04T02:02:36","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/medx-announces-initial-closing-and-proposed-extension-of-non-brokered-private-placement\/"},"modified":"2025-10-04T04:02:36","modified_gmt":"2025-10-04T02:02:36","slug":"medx-announces-initial-closing-and-proposed-extension-of-non-brokered-private-placement","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/medx-announces-initial-closing-and-proposed-extension-of-non-brokered-private-placement\/","title":{"rendered":"MedX announces Initial Closing and Proposed Extension of Non-Brokered Private Placement"},"content":{"rendered":"
\n

MISSISSAUGA, Ontario–(BUSINESS WIRE)–MedX Health Corp.<\/b> (\u201cMedX<\/b>\u201d or the \u201cCompany<\/b>\u201d) (TSX-V: MDX<\/b>) is pleased to announce that it has completed the Initial Closing of the Non-brokered Private Placement to accredited investors announced in its Press Release dated July 25, 2025. The Initial Closing comprised the issuance of 7,033,000 Units (as described below) and raised cash proceeds of $527,500. No commissions were paid and no Agent\u2019s Warrants (as described below) were issued in respect of the Initial Closing. Securities issued are subject to a regulatory \u201chold\u201d period of four months and one day from the date of issuance. Further Closings are anticipated following this Initial Closing, subject to relevant regulatory acceptance. Under this Non-Brokered Private Placement, the Company intends issue of up to a maximum of 33,333,334 Units at $0.075 per Unit (\u201cUnit<\/b>\u201d) to raise a Maximum amount of $2,500,000. Each Unit is comprised of One (1) fully paid common share and One-half (1\/2) of a Share Purchase Warrant; each whole Share Purchase Warrant (\u201cWarrant<\/b>(s<\/b>)\u201d) will be exercisable to purchase One (1) further Common Share at the price of $0.10, during the period of one year commencing on the date of issue. Further Closing(s) of the Placement will be subject to receipt of further subscriptions and a number of other conditions, including without limitation the receipt of all relevant regulatory and Stock Exchange approvals or acceptances. It is anticipated that, subject to compliance with relevant regulatory provisions, certain Insiders will participate in this Placement, in which case the Company will rely on exemptions from formal valuation and minority shareholder approval requirements set out in Multilateral Instrument 61-101 \u2013 Protection of Minority Security Holders in Special Transactions.<\/i> Qualified agents will receive a cash commission equal to 8% of the gross proceeds received by the Company from the sale of the Units to subscribers introduced by such agent(s) and agent\u2019s warrants (\u201cAgent\u2019s Warrant(s)<\/b>\u201d) equal to 8% of subscriptions introduced by such agent(s). Each Agent\u2019s Warrant, which will be non-transferable, will entitle the holder to acquire, at the price of CAD$0.09, a unit, comprised of One (1) fully paid Common Share and one-half (1\/2) of a non-transferable agent\u2019s share purchase warrant; each whole agent\u2019s share purchase warrant (\u201cAgent\u2019s Share Purchase Warrant<\/b>\u201d), will entitle the holder to acquire one additional Common Share at the price of CAD$0.10. The Agent\u2019s Warrants and any Agent\u2019s Share Purchase Warrants that may be issued pursuant to exercise of an Agent\u2019s Warrant, if not exercised, will expire one year following the date of issuance of the original Agent\u2019s Warrant.<\/p>\n

<\/a>
<\/a><\/p>\n

\nThe Company further announced today that, subject to acceptance by the TSX-V, the ultimate Closing Date for the non-brokered Private Placement, will be extended to November 7, 2025. The Company has already received Conditional Acceptance for the placement from the TSX-V, but closing for the full amount of the proposed Placement has been delayed.<\/p>\n

\nFunds raised in this Placement will be directed towards continuing development of the Company\u2019s leading edge SIAscopy\u00ae<\/sup> on DermSecure\u00ae<\/sup> telemedicine platform, building out the launch of its technology into the occupational health marketplace, and general corporate purposes.<\/p>\n

\nAbout MedX Health Corp.:<\/b><\/p>\n

\nMedX Health Corp., headquartered in Ontario, Canada, is a leader in non-invasive skin assessment and teledermatology. Its proprietary SIAscopy\u00ae<\/sup> technology, integrated into the DermSecure\u00ae<\/sup> platform, enables pain-free, accurate imaging of skin lesions for rapid dermatologist review. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformit\u00e9 Europ\u00e9enne, for use in 38 territories worldwide including Canada, the U.S., Australia, New Zealand, the United Kingdom, the European Union and Turkey. MedX\u2019s advanced telemedicine platform enables healthcare professionals to quickly and accurately assess suspicious moles, lesions, and other skin conditions through its proprietary imaging technology, SIAscopy\u00ae<\/sup>, and its secure, cloud-based patient management system, DermSecure\u00ae<\/sup>.<\/p>\n

\nVisit: https:\/\/www.medxhealth.com<\/a><\/p>\n

\nNeither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.<\/i><\/b><\/p>\n

\nThis Media Release may contain forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties.<\/i><\/b><\/p>\n

Contacts<\/b> <\/p>\n

\nMedX Health Corp.
\n
John Gevisser, CEO \u2013 MedX Health Corp.
\n
john.gevisser@medxhealth.com<\/a>
(+1) 905-670-4428<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

MISSISSAUGA, Ontario–(BUSINESS WIRE)–MedX Health Corp. (\u201cMedX\u201d or the \u201cCompany\u201d) (TSX-V: MDX) is pleased to announce that it has completed the Initial Closing of the Non-brokered Private Placement to accredited investors announced in its Press Release dated July 25, 2025. The Initial Closing comprised the issuance of 7,033,000 Units (as described below) and raised cash proceeds … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-61973","6":"format-standard","7":"category-industry"},"yoast_head":"\nMedX announces Initial Closing and Proposed Extension of Non-Brokered Private Placement - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/medx-announces-initial-closing-and-proposed-extension-of-non-brokered-private-placement\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MedX announces Initial Closing and Proposed Extension of Non-Brokered Private Placement - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"MISSISSAUGA, Ontario–(BUSINESS WIRE)–MedX Health Corp. (\u201cMedX\u201d or the \u201cCompany\u201d) (TSX-V: MDX) is pleased to announce that it has completed the Initial Closing of the Non-brokered Private Placement to accredited investors announced in its Press Release dated July 25, 2025. The Initial Closing comprised the issuance of 7,033,000 Units (as described below) and raised cash proceeds ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/medx-announces-initial-closing-and-proposed-extension-of-non-brokered-private-placement\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-04T02:02:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20251003114469\/en\/618221\/22\/MedX_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medx-announces-initial-closing-and-proposed-extension-of-non-brokered-private-placement\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medx-announces-initial-closing-and-proposed-extension-of-non-brokered-private-placement\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"MedX announces Initial Closing and Proposed Extension of Non-Brokered Private Placement\",\"datePublished\":\"2025-10-04T02:02:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medx-announces-initial-closing-and-proposed-extension-of-non-brokered-private-placement\\\/\"},\"wordCount\":714,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medx-announces-initial-closing-and-proposed-extension-of-non-brokered-private-placement\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251003114469\\\/en\\\/618221\\\/22\\\/MedX_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medx-announces-initial-closing-and-proposed-extension-of-non-brokered-private-placement\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medx-announces-initial-closing-and-proposed-extension-of-non-brokered-private-placement\\\/\",\"name\":\"MedX announces Initial Closing and Proposed Extension of Non-Brokered Private Placement - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medx-announces-initial-closing-and-proposed-extension-of-non-brokered-private-placement\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medx-announces-initial-closing-and-proposed-extension-of-non-brokered-private-placement\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251003114469\\\/en\\\/618221\\\/22\\\/MedX_Logo.jpg\",\"datePublished\":\"2025-10-04T02:02:36+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medx-announces-initial-closing-and-proposed-extension-of-non-brokered-private-placement\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medx-announces-initial-closing-and-proposed-extension-of-non-brokered-private-placement\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medx-announces-initial-closing-and-proposed-extension-of-non-brokered-private-placement\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251003114469\\\/en\\\/618221\\\/22\\\/MedX_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251003114469\\\/en\\\/618221\\\/22\\\/MedX_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medx-announces-initial-closing-and-proposed-extension-of-non-brokered-private-placement\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MedX announces Initial Closing and Proposed Extension of Non-Brokered Private Placement\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MedX announces Initial Closing and Proposed Extension of Non-Brokered Private Placement - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/medx-announces-initial-closing-and-proposed-extension-of-non-brokered-private-placement\/","og_locale":"en_US","og_type":"article","og_title":"MedX announces Initial Closing and Proposed Extension of Non-Brokered Private Placement - Pharma Trend","og_description":"MISSISSAUGA, Ontario–(BUSINESS WIRE)–MedX Health Corp. (\u201cMedX\u201d or the \u201cCompany\u201d) (TSX-V: MDX) is pleased to announce that it has completed the Initial Closing of the Non-brokered Private Placement to accredited investors announced in its Press Release dated July 25, 2025. The Initial Closing comprised the issuance of 7,033,000 Units (as described below) and raised cash proceeds ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/medx-announces-initial-closing-and-proposed-extension-of-non-brokered-private-placement\/","og_site_name":"Pharma Trend","article_published_time":"2025-10-04T02:02:36+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20251003114469\/en\/618221\/22\/MedX_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/medx-announces-initial-closing-and-proposed-extension-of-non-brokered-private-placement\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/medx-announces-initial-closing-and-proposed-extension-of-non-brokered-private-placement\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"MedX announces Initial Closing and Proposed Extension of Non-Brokered Private Placement","datePublished":"2025-10-04T02:02:36+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/medx-announces-initial-closing-and-proposed-extension-of-non-brokered-private-placement\/"},"wordCount":714,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/medx-announces-initial-closing-and-proposed-extension-of-non-brokered-private-placement\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20251003114469\/en\/618221\/22\/MedX_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/medx-announces-initial-closing-and-proposed-extension-of-non-brokered-private-placement\/","url":"https:\/\/pharma-trend.com\/en\/medx-announces-initial-closing-and-proposed-extension-of-non-brokered-private-placement\/","name":"MedX announces Initial Closing and Proposed Extension of Non-Brokered Private Placement - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/medx-announces-initial-closing-and-proposed-extension-of-non-brokered-private-placement\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/medx-announces-initial-closing-and-proposed-extension-of-non-brokered-private-placement\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20251003114469\/en\/618221\/22\/MedX_Logo.jpg","datePublished":"2025-10-04T02:02:36+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/medx-announces-initial-closing-and-proposed-extension-of-non-brokered-private-placement\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/medx-announces-initial-closing-and-proposed-extension-of-non-brokered-private-placement\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/medx-announces-initial-closing-and-proposed-extension-of-non-brokered-private-placement\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20251003114469\/en\/618221\/22\/MedX_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20251003114469\/en\/618221\/22\/MedX_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/medx-announces-initial-closing-and-proposed-extension-of-non-brokered-private-placement\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"MedX announces Initial Closing and Proposed Extension of Non-Brokered Private Placement"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61973","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=61973"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61973\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=61973"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=61973"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=61973"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}